Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21879620 | 0.98 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL16264576 | 0.86 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL9407510 | 0.86 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL16439765 | 0.85 | CHRM2 (0.63) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL15859356 | 0.84 | CA2 (0.49) | MEN1KMT2AALDH1A1MAPTCYP1A2 | |
| SCHEMBL8498255 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTCYP1A2CYP2D6BCHE | |
| SCHEMBL4530301 | 0.83 | ALDH1A1 (0.77) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL13995600 | 0.83 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL22365200 | 0.83 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL9034542 | 0.83 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119898789-A | Flower-like sphere mordenite as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-118620358-A | Antifog polyester composite material for packaging film and preparation method thereof | 广东宝佳利新材料股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-220634309-U | Synthesis production line of 4-tert-butyl benzylamine | 上海开荣化工科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-116396192-A | Diurea anti-sagging agent and synthesis method thereof | 天津大学 | 2023-07-07 | — | — | CN | claimed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | claimed |
| CN-106946828-B | Scopolactone phenol ether derivative and its preparation method and application | 西南大学 | 2019-02-26 | — | — | CN | claimed |
| CN-105130823-B | A kind of method of synthesis butenafine | 中国科学技术大学 | 2017-03-01 | — | — | CN | claimed |
| CN-105130823-A | Butenafine synthesis method | USTC UNIV SCIENCE TECH CN | 2015-12-09 | — | — | CN | claimed |
| CN-103360314-B | The new preparation process of tebufenpyrad | JIANG University OF TECHNOLOGY (CN) | 2015-08-05 | — | — | CN | claimed |
| CN-102131815-B | Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate | TIBOTEC PHARMACEUTICALS (IE) | 2014-10-15 | — | — | CN | claimed |
| EP-2346877-B1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | claimed |
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | claimed |
| CN-103360314-A | New preparation method of tebufenpyrad | UNIV ZHEJIANG TECHNOLOGY | 2013-10-23 | — | — | CN | claimed |
| EP-2346877-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | Tibotec Pharmaceuticals (IE) | 2011-07-27 | — | — | EP | claimed |
| CN-102131815-A | Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate | TIBOTEC PHARM LTD | 2011-07-20 | — | — | CN | claimed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | claimed |
| WO-2010023322-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARMACEUTICALS (IE) | 2010-03-04 | — | — | WO | claimed |
| CN-101462970-A | Process for synthesizing chiral methoxybenzylamine | PARLING SHANGHAI PHARM TECHNOL (CN) | 2009-06-24 | — | — | CN | claimed |
| US-4954499-A | Pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-09-04 | — | — | US | claimed |
| WO-2025243322-A1 | A PROCESS FOR PREPARATION OF PRAZIQUANTEL AND INTERMEDIATES THEREFOR | ALIVIRA ANIMAL HEALTH LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119898789-A | Flower-like sphere mordenite as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119643743-A | Method for detecting dimethylketene and application thereof | 江苏虹港石化有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118620358-A | Antifog polyester composite material for packaging film and preparation method thereof | 广东宝佳利新材料股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| CN-220634309-U | Synthesis production line of 4-tert-butyl benzylamine | 上海开荣化工科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-220634309-U | Synthesis production line of 4-tert-butyl benzylamine | 上海开荣化工科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-220634309-U | Synthesis production line of 4-tert-butyl benzylamine | 上海开荣化工科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-113968824-B | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2024-01-19 | — | — | CN | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3795572-B1 | DARUNAVIR PROPIONATE SOLVATE | LAURUS LABS LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| CN-116947645-A | Low-carbon environment-friendly method for synthesizing primary amine by taking halohydrocarbon as raw material | 徐昌平 | 2023-10-27 | — | — | CN | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-111253313-B | Method for preparing pyrazole amide compound by utilizing microreactor | 青岛恒宁生物科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-116396192-A | Diurea anti-sagging agent and synthesis method thereof | 天津大学 | 2023-07-07 | — | — | CN | disclosed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-110709471-B | Additive manufacturing process using amines for post-curing | 科思创德国股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| WO-2021160602-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | WO | disclosed |
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-22 | — | — | US | disclosed |
| WO-2021142474-A1 | COVALENT ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021129629-A1 | ZESTE ENHANCER HOMOLOGUE 2 INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3795572-A1 | DARUNAVIR PROPIONATE SOLVATE | Laurus Labs Limited (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| US-20200370204-A1 | PROPERTY MODULATION WITH CHEMICAL TRANSFORMATIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-11-26 | — | — | US | disclosed |
| EP-2877474-B1 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LTD (IN) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020132566-A1 | STING PYRAZOLE AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| CN-110799566-A | Additive manufacturing method using thermoplastic free-radically crosslinkable building materials | 科思创德国股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
| WO-2020023355-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10544157-B2 | Process for preparation of Darunavir | LAURUS LABS LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| CN-110709471-A | Additive manufacturing process using amines for post-curing | 科思创德国股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-11-21 | — | — | US | disclosed |
| CN-110093061-A | A kind of photosensitive resin and the preparation method and application thereof with maleimide structure | 浙江永太新材料有限公司 | 2019-08-06 | — | — | CN | disclosed |
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2019-05-21 | — | — | US | disclosed |
| US-20190144461-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2019-05-16 | — | — | US | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| CN-106946828-B | Scopolactone phenol ether derivative and its preparation method and application | 西南大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-109314327-A | The manufacturing method of conductive material, connection structural bodies and connection structural bodies | 积水化学工业株式会社 | 2019-02-05 | — | — | CN | disclosed |
| CN-109313956-A | The manufacturing method of conductive material, connection structural bodies and connection structural bodies | 积水化学工业株式会社 | 2019-02-05 | — | — | CN | disclosed |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3019488-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | VIROSTATICS SRL (IT) | 2017-07-20 | — | — | US | disclosed |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | VIROSTATICS SRL (IT) | 2017-07-20 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9617225-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2017-04-11 | — | — | US | disclosed |
| US-9617225-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| CN-105130823-B | A kind of method of synthesis butenafine | 中国科学技术大学 | 2017-03-01 | — | — | CN | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| CN-104926665-B | Method for synthesizing cinacalcet | 中国科学技术大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-104812749-B | Indolecarboxamide derivant as P2X7 receptor antagonist | 埃科特莱茵药品有限公司 | 2016-12-14 | — | — | CN | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| US-9493449-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| CN-103408570-B | Containing the benzene-naphthalene diimide derivative of 1,3-bis-sulfur-2-ylide alkene conjugate unit, preparation method and application | 中国科学院上海有机化学研究所 | 2016-06-29 | — | — | CN | disclosed |
| US-20160143870-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160143870-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3019488-A1 | IDO INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-105517999-A | Ido inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-20 | — | — | CN | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
| CN-105198785-A | Maleimide compound and preparation and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2015-12-30 | — | — | CN | disclosed |
| CN-105130823-A | Butenafine synthesis method | USTC UNIV SCIENCE TECH CN | 2015-12-09 | — | — | CN | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
| CN-104926665-A | Method for synthesizing cinacalcet | USTC UNIV SCIENCE TECH CN | 2015-09-23 | — | — | CN | disclosed |
| CN-103360314-B | The new preparation process of tebufenpyrad | JIANG University OF TECHNOLOGY (CN) | 2015-08-05 | — | — | CN | disclosed |
| CN-104812749-A | Iindole carboxamide derivatives as p2x7 receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-07-29 | — | — | CN | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| CN-104718234-A | Curable composition for electronic component and connection structure | SEKISUI CHEMICAL CO LTD | 2015-06-17 | — | — | CN | disclosed |
| EP-2877474-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | Laurus Labs Private Limited (IN) | 2015-06-03 | — | — | EP | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| CN-104395324-A | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING SA | 2015-03-04 | — | — | CN | disclosed |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| CN-102159207-B | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2015-02-04 | — | — | CN | disclosed |
| WO-2015006520-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006520-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| CN-102131815-B | Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate | TIBOTEC PHARMACEUTICALS (IE) | 2014-10-15 | — | — | CN | disclosed |
| EP-2346877-B1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | disclosed |
| EP-2346877-B1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| WO-2014016660-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2014-01-30 | — | — | WO | disclosed |
| CN-102753522-B | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | disclosed |
| CN-103408570-A | Naphthalimide derivant containing 1, 3-dithiol-2-yliden conjugation unit, preparation method and application | SHANGHAI INST ORGANIC CHEM | 2013-11-27 | — | — | CN | disclosed |
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | disclosed |
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | disclosed |
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | disclosed |
| CN-103360314-A | New preparation method of tebufenpyrad | UNIV ZHEJIANG TECHNOLOGY | 2013-10-23 | — | — | CN | disclosed |
| CN-102281864-B | Beta-amino ester compounds and uses thereof | LIVING PROOF INC | 2013-10-16 | — | — | CN | disclosed |
| CN-101370765-B | Method for selectively producing primary amine | SUMITOMO CHEMICAL CO | 2013-03-13 | — | — | CN | disclosed |
| WO-2013011485-A1 | PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-24 | — | — | WO | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| CN-102753522-A | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | disclosed |
| CN-101142174-B | Novel compound as vanilloid receptor antagonist, isomer thereof or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the same | AMOREPACIFIC CORP | 2012-05-09 | — | — | CN | disclosed |
| CN-101462970-B | Process for synthesizing chiral methoxybenzylamine | BAILING PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2012-02-08 | — | — | CN | disclosed |
| CN-102281864-A | Beta-amino ester compounds and uses thereof | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-10-20 | — | — | US | disclosed |
| EP-2371967-A1 | Production of carotenoids in oleaginous yeast and fungi | DSM IP Assets B.V. (NL) | 2011-10-05 | — | — | EP | disclosed |
| CN-102159207-A | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2011-08-17 | — | — | CN | disclosed |
| EP-2346877-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | Tibotec Pharmaceuticals (IE) | 2011-07-27 | — | — | EP | disclosed |
| CN-102131815-A | Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate | TIBOTEC PHARM LTD | 2011-07-20 | — | — | CN | disclosed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | disclosed |
| CN-101333218-B | Formamide alkylbenzene substituted mercapto pyrrolidine carbapenem compounds | SHANDONG XUANZHU PHARM TECH CO | 2011-05-18 | — | — | CN | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2267046-A1 | Process for homo- or copolymerization of conjugated olefines | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| CN-101842356-A | Polymorphs of (3- (((4-tert-butylbenzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or hydrate thereof and process for producing the same | PFIZER PROD INC | 2010-09-22 | — | — | CN | disclosed |
| CN-101821238-A | Suppress the active isophthaloyl sulfonamide derivatives of beta-secretase (BETA-SECRETASE) | COMENTIS INC | 2010-09-01 | — | — | CN | disclosed |
| CN-101367819-B | 5-substituent-2-(4-substituted phenyl)-6,7-dihydrogen pyrazole-[1,5-a]pyrazine-4(5H)-ketone derivant and uses thereof | UNIV SHANDONG | 2010-08-18 | — | — | CN | disclosed |
| EP-2205596-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | disclosed |
| CN-101679370-A | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | GRUENENTHAL GMBH | 2010-03-24 | — | — | CN | disclosed |
| WO-2010023322-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARMACEUTICALS (IE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010023322-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARMACEUTICALS (IE) | 2010-03-04 | — | — | WO | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| CN-100537528-C | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2009-09-09 | — | — | CN | disclosed |
| CN-101462970-A | Process for synthesizing chiral methoxybenzylamine | PARLING SHANGHAI PHARM TECHNOL (CN) | 2009-06-24 | — | — | CN | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| CN-101367819-A | 5-substituent-2-(4-substituted phenyl)-6,7-dihydrogen pyrazole-[1,5-a]pyrazine-4(5H)-ketone derivant and uses thereof | UNIV SHANDONG (CN) | 2009-02-18 | — | — | CN | disclosed |
| CN-101370765-A | Method for selectively producing primary amine | SUMITOMO CHEMICAL CO (JP) | 2009-02-18 | — | — | CN | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| CN-101333218-A | Formamide alkylbenzene substituted mercapto pyrrolidine carbapenem compounds | SHANDONG XUANZHU MEDICAL SCI T (CN) | 2008-12-31 | — | — | CN | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080107598-A1 | Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications | COLIP, GREGORY RUSSELL | 2008-05-08 | — | — | US | disclosed |
| CN-101142174-A | Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising the same | AMOREPACIFIC CORP (KR) | 2008-03-12 | — | — | CN | disclosed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| CN-1326903-C | Hydrophilized blocked polyisocyanates | BAYER MATERIALSCIENCE AG (DE) | 2007-07-18 | — | — | CN | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| CN-1948359-A | Reaction system, preparation and application thereof | BAYER MATERIALSCIENCE AG (DE) | 2007-04-18 | — | — | CN | disclosed |
| CN-1301981-C | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1438310-B1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| US-20060247261-A1 | Pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | US | disclosed |
| CN-1852891-A | 4- (methylsulfonylamino) phenyl analogues as vanilloid antagonists with high analgesic activity and pharmaceutical compositions containing them | GRUENENTHAL GMBH (DE) | 2006-10-25 | — | — | CN | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| CN-1793121-A | Fused salt containing asymmetrical sulfonium cation, its preparation process and application in electrochemical device | UNIV SHANGHAI JIAOTONG (CN) | 2006-06-28 | — | — | CN | disclosed |
| CN-1729223-A | Hydrophilized blocked polyisocyanates | BAYER MATERIALSCIENCE AG (DE) | 2006-02-01 | — | — | CN | disclosed |
| EP-1597292-A2 | PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| CN-1662487-A | Amide linker peroxisome proliferator-activated receptor modulators | LILLY CO ELI (US) | 2005-08-31 | — | — | CN | disclosed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. | 2005-05-05 | — | — | US | disclosed |
| CN-1169795-C | Nitrogenous heterocyclic compounds | Э�ͷ���ҵ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| WO-2004076504-A2 | PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| CN-1514831-A | Medicinal composition containing 1,3-thiazine derivative | ��Ұ����ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| CN-1138761-C | 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and use as dopamine autoreceptor (D2) agonists | — | 2004-02-18 | — | — | CN | disclosed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | disclosed |
| CN-1131202-C | Calcium receptor-active compounds | KIRIN BREWERY (JP) | 2003-12-17 | — | — | CN | disclosed |
| EP-0900211-B1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | UPJOHN CO (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| CN-1387519-A | 2-imino-1, 3-thiazine derivatives | SHIONOGI & CO (JP) | 2002-12-25 | — | — | CN | disclosed |
| WO-2002100842-A1 | SULFONYLOXAZOLAMINES AND THEIR USE AS 5-HT6 LIGANDS | MERCK PATENT GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| CN-1072935-C | Preparation method for medicinal composition containing aza-steroid compound for treating prostatic hyperplasia | SANKYO CO (JP) | 2001-10-17 | — | — | CN | disclosed |
| CN-1308608-A | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 | ABBOTT LAB (US) | 2001-08-15 | — | — | CN | disclosed |
| CN-1306011-A | Polyaddition catalyst component, polyaddition catalyst and method for preparing addition polymer | SUMITOMO CHEMICAL CO (JP) | 2001-08-01 | — | — | CN | disclosed |
| US-6177438-B1 | ANALGESICS, DIURETICS, ANTITUSSIVE AGENTS | TORAY INDUSTRIES, INC. (JP) | 2001-01-23 | — | — | US | disclosed |
| US-6147084-A | Brain cell protective agent | TORAY INDUSTRIES, INC. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0519353-B1 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-08-16 | — | — | EP | disclosed |
| CN-1053672-C | Azasteroid compounds for the treatment of prostatic hypertrophy | SANKYO CO (JP) | 2000-06-21 | — | — | CN | disclosed |
| CN-1252060-A | 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and use as dopamine autoreceptor (D2) agonists | AMERICAN HOME PROD (US) | 2000-05-03 | — | — | CN | disclosed |
| US-5972953-A | MORPHINAN DERIVATIVE; USEFAL AS PREVENTIVE AND THERAPUETIC AGENTS OF ISCHEMIC BRAIN DISORDERS, BRAIN NERVE CELL DISORDERS AND DEMENTIA | TORAY INDUSTRIES, LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| CN-1225083-A | Calcium receptor-active compounds | KIRIN BREWERY (JP) | 1999-08-04 | — | — | CN | disclosed |
| CN-1043992-C | Process for preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-07-07 | — | — | CN | disclosed |
| EP-0900211-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| CN-1209319-A | Preparation method for medicinal composition containing aza-steroid compound for treating prostatic hyperplasia | SANKYO CO (JP) | 1999-03-03 | — | — | CN | disclosed |
| CN-1042226-C | Heterocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-24 | — | — | CN | disclosed |
| CN-1208404-A | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO KK (JP) | 1999-02-17 | — | — | CN | disclosed |
| CN-1041095-C | Steroid compound and pharmaceutical composition for treating prostatic hypertrophy | SANKYO CO (JP) | 1998-12-09 | — | — | CN | disclosed |
| US-5847148-A | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0717742-B1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-11 | — | — | EP | disclosed |
| EP-0661283-B1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES (JP) | 1998-10-21 | — | — | EP | disclosed |
| CN-1195666-A | Intermediates of steroids, their preparation and uses | SANKYO CO (JP) | 1998-10-14 | — | — | CN | disclosed |
| US-5780633-A | Process for the preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5760025-A | ADMINISTERING TESTOSTERONE 5A-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5698720-A | INTERMEDIATES FOR TESTOSTERONE 5-ALPHA-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0751767-A4 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997040031-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0751767-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| EP-0736037-A1 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-$g(a)-AMINOALKANOYL-(S)-N-$g(a)-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS | THE COCA-COLA COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| CN-1130907-A | Process for preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-09-11 | — | — | CN | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| EP-0717742-A1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
| CN-1030701-C | Indole derivatives and process for production thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-01-17 | — | — | CN | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| EP-0661283-A1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES, INC. (JP) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995007279-A2 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
| US-5334716-A | Preventing testosteron 5a-reductase mediated diseases; alopecia, acne, prostatism | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| EP-0600084-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5312829-A | Testosterone 5alpha-reductase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| CN-1083070-A | Steroid derivatives for the treatment of prostatic hypertrophy, process for their preparation and their use | SANKYO CO (JP) | 1994-03-02 | — | — | CN | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| WO-1993003012-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
| CN-1067893-A | Hete rocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-01-13 | — | — | CN | disclosed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
| CN-1062145-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1992-06-24 | — | — | CN | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| CN-1015178-B | PROCESS AND INTERMEDIATES FOR BETA-LACTAM ANTIBIOTICS | HARVARD COLLEGE (US) | 1991-12-25 | — | — | CN | disclosed |
| CN-1015103-B | PROCESS FOR PREPARING 3-HALO-1-CARBO-3-CEPHEM-4-CARBOXYLIC ACID AND ITS DERIV. | HARVARD COLLEGE (US) | 1991-12-18 | — | — | CN | disclosed |
| CN-1056685-A | Indole derivatives and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-04 | — | — | CN | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| EP-0212535-B1 | N6-DISUBSTITUTED PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1991-05-29 | — | — | EP | disclosed |
| US-4954499-A | Pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-09-04 | — | — | US | disclosed |
| US-4757050-A | Urea, amide group-containing | E. R. SQUIBB SONS, INC. (US) | 1988-07-12 | — | — | US | disclosed |
| US-4749792-A | Diamino ketones and alcohols as analgesic agents | E. R. SQUIBB & SONS, INC. (US) | 1988-06-07 | — | — | US | disclosed |
| CN-86104783-A | The method for preparing beta-Lactam antibiotics | — | 1987-02-04 | — | — | CN | disclosed |
| CN-86105247-A | Antibiotic intermediate and preparation method | — | 1987-02-04 | — | — | CN | disclosed |
| US-4442286-A | Preparation of amines by the reduction of imines with phosphorous acid | PETROLITE CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
| US-4352696-A | Process and composition | THE UPJOHN COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
| EP-0007717-B1 | CLAVULANIC ACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1982-08-11 | — | — | EP | disclosed |
| US-4257995-A | STORAGE STABILITY | THE UPJOHN COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
| US-4235809-A | α-Amino phosphonic acids | PETROLITE CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
| EP-0007717-A1 | Clavulanic acid derivatives, a process for their preparation, their use, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-02-06 | — | — | EP | disclosed |
| US-4182887-A | ANTIPHLOGISTIC, ANTITHROMBOTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1980-01-08 | — | — | US | disclosed |
| US-4182887-A | ANTIPHLOGISTIC, ANTITHROMBOTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | DUT, UMPS, DPYD | MEN1 4820/4885KMT2A 1615/4885ALDH1A1 872/4885 |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | MEN1 3333/4885KMT2A 3049/4885ALDH1A1 1182/4885 |
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | MEN1 3792/4885KMT2A 3692/4885ALDH1A1 3312/4885 |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | MEN1 1372/4885KMT2A 3655/4885ALDH1A1 3511/4885 |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | MEN1 3487/4885KMT2A 1187/4885ALDH1A1 2254/4885 |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885ALDH1A1 1546/4885 |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | MEN1 521/4885KMT2A 2276/4885ALDH1A1 29/4885 |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | MEN1 2485/4885KMT2A 2837/4885ALDH1A1 3422/4885 |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | MEN1 2935/4885KMT2A 734/4885ALDH1A1 513/4885 |
| US-20190144461-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | MEN1 4858/4885KMT2A 4163/4885ALDH1A1 1810/4885 |
| US-11739121-B2 | EPHA2 agonists and uses thereof | EPHA2, EPHB2, EPHA6 | MEN1 3461/4885KMT2A 1626/4885ALDH1A1 4008/4885 |
| US-20080107598-A1 | Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications | TNNI3, CAD, TNNT2 | MEN1 214/4885KMT2A 1922/4885ALDH1A1 2581/4885 |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885ALDH1A1 222/4885 |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | HTR3C, HPD, HAAO | MEN1 4859/4885KMT2A 2401/4885ALDH1A1 317/4885 |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | MEN1 4339/4885KMT2A 2194/4885ALDH1A1 4542/4885 |
| US-10544157-B2 | Process for preparation of Darunavir | SAMHD1, CYP3A5, DARS1 | MEN1 4858/4885KMT2A 4163/4885ALDH1A1 1810/4885 |
| US-20160143870-A1 | IDO INHIBITORS | IDO1, IDO2, TDO2 | MEN1 1664/4885KMT2A 572/4885ALDH1A1 435/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | MEN1 3448/4885KMT2A 2112/4885ALDH1A1 2142/4885 |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | MEN1 2485/4885KMT2A 2837/4885ALDH1A1 3422/4885 |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, DARS1, CYP3A43 | MEN1 4867/4885KMT2A 4352/4885ALDH1A1 2031/4885 |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | MEN1 1057/4885KMT2A 1467/4885ALDH1A1 3947/4885 |
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | EPHA2, EPHB2, EPHA6 | MEN1 3429/4885KMT2A 1673/4885ALDH1A1 3979/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | MEN1 3470/4885KMT2A 1142/4885ALDH1A1 1621/4885 |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | MEN1 336/4885KMT2A 4111/4885ALDH1A1 4305/4885 |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | MEN1 4858/4885KMT2A 4163/4885ALDH1A1 1810/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | MEN1 3687/4885KMT2A 956/4885ALDH1A1 1283/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | MEN1 1036/4885KMT2A 556/4885ALDH1A1 373/4885 |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | MEN1 1036/4885KMT2A 556/4885ALDH1A1 373/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | MEN1 4636/4885KMT2A 3095/4885ALDH1A1 298/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MEN1 2963/4885KMT2A 4104/4885ALDH1A1 233/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885KMT2A 4432/4885ALDH1A1 2228/4885 |
| US-20110257185-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | MEN1 336/4885KMT2A 4111/4885ALDH1A1 4305/4885 |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | MEN1 3945/4885KMT2A 1493/4885ALDH1A1 1223/4885 |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | MEN1 3470/4885KMT2A 1142/4885ALDH1A1 1621/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | MEN1 1213/4885KMT2A 64/4885ALDH1A1 2056/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MEN1 2895/4885KMT2A 4715/4885ALDH1A1 2115/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | MEN1 3139/4885KMT2A 1860/4885ALDH1A1 1594/4885 |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | DPYD, ABL1, BRD4 | MEN1 4027/4885KMT2A 219/4885ALDH1A1 507/4885 |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885ALDH1A1 1546/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885ALDH1A1 1546/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | MEN1 1213/4885KMT2A 64/4885ALDH1A1 2056/4885 |
| US-20060247261-A1 | Pyrimidine compounds | CNR2, CNR1, P2RX5 | MEN1 4669/4885KMT2A 2825/4885ALDH1A1 3083/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MEN1 2963/4885KMT2A 4104/4885ALDH1A1 233/4885 |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | MEN1 4360/4885KMT2A 4180/4885ALDH1A1 1546/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | MEN1 3285/4885KMT2A 2306/4885ALDH1A1 222/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | MEN1 811/4885KMT2A 1237/4885ALDH1A1 543/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | MEN1 4473/4885KMT2A 2623/4885ALDH1A1 1430/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | MEN1 154/4885KMT2A 4432/4885ALDH1A1 2228/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | MEN1 1388/4885KMT2A 4426/4885ALDH1A1 269/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MEN1 2895/4885KMT2A 4715/4885ALDH1A1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.